What baseline laboratory tests should be obtained before initiating hormone replacement therapy?

Baseline Laboratory Testing Before Hormone Replacement Therapy

The specific baseline labs required depend entirely on the type of hormone replacement being initiated—testosterone therapy requires PSA, hematocrit, lipids, and liver function tests, while estrogen therapy requires different monitoring focused on cardiovascular and thrombotic risk factors.

For Testosterone Replacement Therapy

Essential Baseline Labs 1

Before initiating testosterone therapy in hypogonadal men, obtain:

• Morning total testosterone (between 8-10 AM) to confirm hypogonadism
• Complete blood count (CBC) with hematocrit—critical because testosterone increases red blood cell production and polycythemia is a common adverse effect
• Prostate-specific antigen (PSA) and digital rectal examination in men over 40 or those at risk for prostate cancer
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Liver function tests (ALT, AST, alkaline phosphatase, bilirubin)
• Fasting glucose or HbA1c if diabetic or at risk for diabetes

Additional Considerations for Testosterone 2, 1

The 2004 New England Journal of Medicine guidance and 2018 Endocrine Society guideline both emphasize that men with abnormal baseline PSA (>4.0 ng/mL) or abnormal digital rectal examination must undergo prostate biopsy before starting testosterone 2. This is non-negotiable—testosterone is contraindicated until prostate cancer is excluded.

For men with HIV and low testosterone, the same baseline labs apply, though CD4+ counts and viral load monitoring continue per HIV protocols 1.

For Estrogen Replacement Therapy (Transgender Women)

Essential Baseline Labs 3

The 2009 Endocrine Society guideline for transsexual persons specifies:

• Baseline testosterone and estradiol levels
• Complete blood count
• Liver function tests (ALT, AST, alkaline phosphatase)—estrogen is metabolized hepatically and can cause liver dysfunction
• Lipid panel (fasting)
• Fasting blood glucose if family history of diabetes
• Prolactin level—estrogen therapy can stimulate pituitary lactotroph growth and cause prolactinomas 3

Cardiovascular Risk Assessment 3

Because estrogen increases thromboembolic risk, evaluate cardiovascular risk factors at baseline. While the guideline doesn't mandate specific thrombophilia testing for all patients, obtain a detailed personal and family history of venous thromboembolism, stroke, or cardiovascular disease. If positive, consider thrombophilia screening before initiating estrogen.

For Estrogen Replacement in Menopausal Women

Core Baseline Testing 4, 5

Recent evidence supports a tiered approach:

Standard tier (all patients):

• FSH and estradiol to confirm menopausal status 5
• Mammography to exclude breast malignancy 5
• Lipid profile (total cholesterol, LDL, HDL, triglycerides) 4, 5
• Fasting glucose or HbA1c for metabolic assessment 4

High-risk tier (add for patients with risk factors):

• Bone mineral density (BMD) if risk factors for osteoporosis present 4
• Bone turnover markers (β-CTX, PINP) in combination with BMD for fracture risk assessment 4
• C-reactive protein for cardiovascular risk stratification 4
• Coagulation studies if personal or family history suggests thrombophilia 6

The 2026 Nigerian Journal of Clinical Practice review emphasizes that single FSH/estradiol measurements have limited value due to cyclic fluctuations in perimenopause—use them for staging but not as sole decision-making tools 4.

For Hypopituitarism (Multiple Hormone Deficiencies)

Comprehensive Baseline Assessment 7

When replacing multiple pituitary hormones, the 2016 Endocrine Society hypopituitarism guideline requires:

• Morning cortisol and ACTH (8 AM)—assess before starting any other hormone replacement
• TSH and free T4
• LH, FSH, testosterone (men) or estradiol (premenopausal women)
• IGF-1 if growth hormone deficiency suspected
• Electrolytes (sodium, potassium, calcium, magnesium, bicarbonate)
• Prolactin
• Complete blood count
• Liver function tests
• Lipid panel
• Fasting glucose

Critical Sequencing 7, 8

Always assess and replace adrenal insufficiency BEFORE starting thyroid hormone replacement—thyroid hormone accelerates cortisol metabolism and can precipitate adrenal crisis in undiagnosed adrenal insufficiency 7, 8. This is a potentially fatal error.

Common Pitfalls to Avoid

1. Starting thyroid hormone before excluding adrenal insufficiency in hypopituitarism—can cause adrenal crisis 7

2. Failing to obtain baseline PSA before testosterone in men over 40—misses opportunity to exclude prostate cancer 2, 1

3. Not checking hematocrit before testosterone—polycythemia is dose-dependent and common 1

4. Relying on single FSH measurement in perimenopause—values fluctuate widely 4

5. Starting estrogen without cardiovascular risk assessment in patients with thrombotic history—increases VTE risk significantly 3

6. Forgetting prolactin monitoring in transgender women on estrogen—pituitary adenomas can develop 3

Special Populations

Bone Health Screening 7, 9

Obtain baseline BMD if:

• Previous fragility fracture
• Family history of osteoporosis
• Chronic glucocorticoid use
• Prolonged hypogonadism
• Age >60 in those non-compliant with hormone therapy 3

The 2012 Endocrine Society osteoporosis guideline recommends measuring serum calcium, phosphate, creatinine, alkaline phosphatase, 25-hydroxyvitamin D, and 24-hour urinary calcium when evaluating men for osteoporosis before treatment 9.

Transgender-Specific Considerations 3, 10

For transgender men on testosterone:

• Monitor estradiol during first 6 months or until uterine bleeding stops for 6 months—levels should be <50 pg/mL 3
• If cervical tissue present, continue annual Pap smears 3
• Consider mammography if mastectomy not performed 3

The 2025 Clinical Chemistry review notes that reference ranges shift with gender-affirming hormone therapy—after establishment on therapy, use reference ranges aligned with affirmed gender for hemoglobin, creatinine, and cardiac biomarkers 10.